Melanoma biopsy: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) No edit summary |
YazanDaaboul (talk | contribs) No edit summary |
||
Line 29: | Line 29: | ||
{{familytree | | | | | | | | | E01 | | | | | | | | | | | | | E01=Melanoma confirmed}} | {{familytree | | | | | | | | | E01 | | | | | | | | | | | | | E01=Melanoma confirmed}} | ||
{{familytree | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|.| | }} | {{familytree | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|.| | }} | ||
{{familytree | F01 | | F02 | | F03 | | F04 | | F05 | | F06 | F01=Breslow thickness| | {{familytree | F01 | | F02 | | F03 | | F04 | | F05 | | F06 | F01=Breslow thickness|F02=Ulceration status|F03=Mitotic rate|F04=Depth and peripheral margin status|F05=Presence of satellitosis|F06=Clark level for lesions ≤ 1 mm}} | ||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | G01 | | | | | | | | | | | | | G01=Reassessment with complete physical examination, including neurological exam and lymph node assessment}} | {{familytree | | | | | | | | | G01 | | | | | | | | | | | | | G01=Reassessment with complete physical examination, including neurological exam and lymph node assessment}} |
Revision as of 00:38, 22 August 2015
Melanoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Melanoma biopsy On the Web |
American Roentgen Ray Society Images of Melanoma biopsy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.
Overview
Biopsy
- Patients who have lesions suspected to be melanoma should always be biopsied.
- An excisional biopsy (either elliptical, punch, or saucerization) of the thickest portion of the lesion with 1-3 mm margins is recommended.
- Shave biopsy is acceptable only when the index of suspicion for melanoma is low.
- The following should be reported when a biopsy is being reported:
- Location
- Regression
- Tumor infiltrating lymphocytes
- Breslow thickness and vertical growth phase
- Histologic ulceration
- Clark level
- Angiolymphatic invasion
- Neurotropism
- Histologic subtype
Suspicious pigmented lesion | |||||||||||||||||||||||||||||||||||||||||||||||
Biopsy | |||||||||||||||||||||||||||||||||||||||||||||||
Inadequate | |||||||||||||||||||||||||||||||||||||||||||||||
Rebiopsy | |||||||||||||||||||||||||||||||||||||||||||||||
Melanoma confirmed | |||||||||||||||||||||||||||||||||||||||||||||||
Breslow thickness | Ulceration status | Mitotic rate | Depth and peripheral margin status | Presence of satellitosis | Clark level for lesions ≤ 1 mm | ||||||||||||||||||||||||||||||||||||||||||
Reassessment with complete physical examination, including neurological exam and lymph node assessment | |||||||||||||||||||||||||||||||||||||||||||||||
Staging | |||||||||||||||||||||||||||||||||||||||||||||||